Financing ·
Clearmind Medicine Inc. entered into an agreement on June 12, 2026, to issue and sell convertible promissory notes to…
CMNDClearmind Medicine Inc.
Clearmind Medicine Inc. entered into an agreement on June 12, 2026, to issue and sell convertible promissory notes to CLA Investors for an aggregate principal amount of $1,000,000. The purchase price is $900,000 in cash, representing 90% of the principal. This transaction amends the existing securities purchase agreements and establishes a $1.875 per common share floor price for the conversion formula. The deal is expected to close around June 14, 2026. Clearmind Medicine Inc. is a biotechnology company focused on developing medicines for mental health.